JAZZ logo

Jazz Pharmaceuticals plc (JAZZ)

$239.77

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on JAZZ

Market cap

$15.39B

EPS

3.07

P/E ratio

14.8

Price to sales

3.08

Dividend yield

--

Beta

0.386646

Price on JAZZ

Previous close

$241.55

Today's open

$243.30

Day's range

$238.94 - $244.61

52 week range

$156.95 - $266.38

Profile about JAZZ

CEO

Renee Gala

Employees

2890

Headquarters

Dublin 4,

Exchange

Nasdaq Global Select

Shares outstanding

64189052

Issue type

Common Stock

JAZZ industries and sectors

Healthcare

Biotechnology & Life Sciences

News on JAZZ

Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • 7 hours ago

news preview

Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock

Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

news source

Zacks Investment Research • Nov 9, 2026

news preview

JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View

Jazz Pharmaceuticals beat Q3 2026 revenue and earnings estimates, driven by oncology and rare sleep growth, and raises its full-year sales outlook.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

DUBLIN, Nov. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Jefferies London Global Healthcare Conference on Tuesday, November 17, 2026, at 8:00 a.m. ET Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026, at 8:00 a.m.

news source

PRNewsWire • Nov 3, 2026

news preview

4 Biotech Stocks Seeing Unusual Options Volume Today

Four pharmaceutical and biotech stocks are seeing unusual options activity today, with Inovio Pharmaceuticals Inc (NASDAQ:INO), Aquestive Therapeutics Inc (NASDAQ:AQST), X4 Pharmaceuticals Inc (NASDAQ:XFOR), and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) all drawing elevated volume.

news source

Schaeffers Research • Nov 3, 2026

news preview

Jazz Pharmaceuticals Q3 Earnings Call Highlights

Jazz Pharmaceuticals NASDAQ: JAZZ reported record third-quarter revenue of $1.24 billion, up 10% from a year earlier, and raised its full-year 2026 revenue outlook as growth in its sleep and oncology businesses offset product-specific pressures and continued investment in its pipeline.

news source

MarketBeat • Nov 3, 2026

news preview

Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript

Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 3, 2026

news preview

Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results

– Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) – – Company raises full year 2026 total revenue guidance – – Ziihera® launched in HER2+ 1L mGEA – – Xywav® revenues grew 12% YoY with 425 net patient adds in 3Q26 – – Closed Actio acquisition, adding ABS-1230 (JZP6979) to rare epilepsy portfolio – DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2026 (3Q26). "Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.

news source

PRNewsWire • Nov 2, 2026

news preview

Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates

Jazz Pharmaceuticals (JAZZ) came out with a quarterly loss of $3.88 per share versus the Zacks Consensus Estimate of a loss of $4.09. This compares to earnings of $8.13 per share a year ago.

news source

Zacks Investment Research • Nov 2, 2026

news preview

Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

news source

Zacks Investment Research • Nov 3, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Jazz Pharmaceuticals plc

Open an M1 investment account to buy and sell Jazz Pharmaceuticals plc commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in JAZZ on M1